HEART
Vitadello M, Sorge M, Percivalle E, Germinario E, Danieli-Betto D, Turco E, Tarone G, Brancaccio M, Gorza L. Loss of melusin is a novel, neuronal NO synthase/FoxO3-independent master switch of unloading-induced muscle atrophy. J Cachexia Sarcopenia Muscle. 2020 Mar 10. doi: 10.1002/jcsm.12546. [Epub ahead of print] PMID: 32154658
Penna C, Sorge M, Femminò S, Pagliaro P, Brancaccio M. Redox Aspects of Chaperones in Cardiac Function. Front Physiol. 2018 Mar 16;9:216. doi: 10.3389/fphys.2018.00216. PubMed PMID: 29615920.
Sorge M, Brancaccio M. Melusin Promotes a Protective Signal Transduction Cascade in Stressed Hearts. Front Mol Biosci. 2016 Sep 12;3:53. doi:10.3389/fmolb.2016.00053.
Tarone G, Brancaccio M. The muscle-specific chaperone protein melusin is a potent cardioprotective agent. Basic Res Cardiol. 2015 Mar;110(2):466. doi: 10.1007/s00395-015-0466-9. Epub 2015 Feb 5.
Penna C*, Brancaccio M*, Tullio F, Rubinetto C, Perrelli MG, Angotti C, Pagliaro P, Tarone G. Overexpression of the muscle-specific protein, melusin, protects from cardiac ischemia/reperfusion injury. Basic Res Cardiol. 2014 Jul;109(4):418. doi: 10.1007/s00395-014-0418-9. Epub 2014 May 25.
Tarone G, Brancaccio M. Keep your heart in shape: molecular chaperone networks for treating heart disease. Cardiovasc Res. 2014 Jun 1;102(3):346-61. doi: 10.1093/cvr/cvu049.
Tarone G, Sbroggiò M, Brancaccio M. Key role of ERK1/2 molecular scaffolds in heart pathology. Cell Mol Life Sci. 2013 Nov;70(21):4047-54. doi: 10.1007/s00018-013-1321-5. Epub 2013 Mar 27.
Ferretti R, Sbroggiò M, Di Savino A, Fusella F, Bertero A, Michowski W, Tarone G, Brancaccio M. Morgana and Melusin: Two fairies chaperoning signal transduction. Cell Cycle. 2011 Nov 1;10(21):3678-83. doi: 10.4161/cc.10.21.18202. Epub 2011 Nov 1.
Sbroggiò M, Bertero A, Velasco S, Fusella F, De Blasio E, Bahou WF, Silengo L, Turco E, Brancaccio M*, Tarone G*. ERK1/2 activation in heart is controlled by melusin, focal adhesion kinase and the scaffold protein IQGAP1. J Cell Sci. 2011, 124:3515-24.
Mauro Sbroggiò, Roberta Ferretti, Elena Percivalle, Malgorzata Gutkowska, Alicja Zylicz, Wojciech Michowski, Jacek Kuznicki, Federica Accornero, Beniamina Pacchioni, Gerolamo Lanfranchi, Jorg Hamm, Emilia Turco, Lorenzo Silengo, Guido Tarone and Mara Brancaccio. The mammalian CHORD-containing protein melusin is a stress response protein interacting with Hsp90 and Sgt1. (2008) FEBS Lett. 582:1788-1794
Mara Brancaccio, Emilio Hirsch, Antonella Notte, Giulio Selvetella, Giuseppe Lembo, Guido Tarone. Integrin signalling: The tug-of-war in heart hypertrophy. (2006) Cardiovasc Res.,70:422-33
Mara Brancaccio, Nadia Menini, Daniela Bongioanni, Roberta Ferretti, Marika De Acetis, Lorenzo Silengo, Guido Tarone. Chp-1 and melusin, two CHORD containing proteins in vertebrates (2003). FEBS Lett., 551: 47-52.
Mara Brancaccio, Luigi Fratta, Antonella Notte, Emilio Hirsch, Roberta Poulet, Simona Guazzone, Marika De Acetis, Carmine Vecchione, Gennaro Marino, Fiorella Altruda, Lorenzo Silengo, Guido Tarone & Giuseppe Lembo. Melusin, a muscle-specific integrin β1–interacting protein, is required to prevent cardiac failure in response to chronic pressure overload (2003). Nat Med; 9:68-75
Mara Brancaccio, Simona Guazzone, Nadia Menini, Elena Sibona, Emilio Hirsch, Marco De Andrea, Mariano Rocchi, Fiorella Altruda, Guido Tarone, Lorenzo Silengo. Melusin is a new muscle-specific interactor for b1 integrin cytoplasmic domain. (1999) J. Biol. Chem 274:29282-29288
CANCER
Fusella F, Seclì L, Cannata C, Brancaccio M. The one thousand and one chaperones of the NF-κB pathway. Cell Mol Life Sci. 2019 Dec 6. doi: 10.1007/s00018-019-03402-z. [Epub ahead of print] Review.
Fusella F, Seclì L, Brancaccio M. Escaping NK cells and recruiting neutrophils: How Morgana/NF-κB signaling promotes metastasis. Mol Cell Oncol. 2018 Jan 30;5(3):e1432258. doi: 10.1080/23723556.2018.1432258. eCollection 2018. PubMed PMID: 30250889.
Rocca S, Carrà G, Poggio P, Morotti A, Brancaccio M. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol Cancer. 2018 Feb 19;17(1):40. doi:10.1186/s12943-018-0774-4. Review. PubMed PMID: 29455651.
Fusella F, Seclì L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-Grand M, Singh V, Chiorino G, Silengo L, Altruda F, Turco E, Morotti A, Oliviero S, Castellano I, Cavallo F, Provero P, Tarone G, Brancaccio M. The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis. Nat Commun. 2017 Nov 21;8(1):1636. doi:10.1038/s41467-017-01829-1. PubMed PMID: 29158506.
Morotti A, Rocca S, Carrà G, Saglio G, Brancaccio M. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. Blood Rev. 2016 Nov 24. pii: S0268-960X(16)30034-0. doi: 10.1016/j.blre.2016.11.004
Brancaccio, M., Rocca, S., Secli, L., Busso, E. and Fusella, F. The double face of Morgana in tumorigenesis. Oncotarget. 2015 Dec 15;6(40):42603-12. doi: 10.18632/oncotarget.6058.
Di Savino A, Panuzzo C, Rocca S, Familiari U, Piazza R, Crivellaro S, Carrà G, Ferretti R, Fusella F, Giugliano E, Camporeale A, Franco I, Miniscalco B, Cutrin JC, Turco E, Silengo L, Hirsch E, Rege-Cambrin G, Gambacorti-Passerini C, Pandolfi PP, Papotti M, Saglio G, Tarone G, Morotti A, Brancaccio M. Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood. 2015 Feb 12. pii: blood-2014-05-575001. Epub 2015 Feb 12.
Fusella F, Ferretti R, Recupero D, Rocca S, Di Savino A, Tornillo G, Silengo L, Turco E, Cabodi S, Provero P, Pandolfi PP, Sapino A, Tarone G, Brancaccio M. Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol. 2014 Oct;234(2):152-63. doi: 10.1002/path.4341. Epub 2014 Aug 6.
Ferretti R, Palumbo V, Di Savino A, Velasco S, Sbroggiò M, Sportoletti P, Micale L, Turco E, Silengo L, Palumbo G, Hirsch E, Teruya-Feldstein J, Bonaccorsi S, Pandolfi PP, Gatti M, Tarone G, Brancaccio M. Morgana/chp-1, a ROCK Inhibitor Involved in Centrosome Duplication and Tumorigenesis. (2010) Dev Cell 18: 486–495.
